Biofrontera Operating Expenses 2021-2025 | BFRI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Biofrontera operating expenses from 2021 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Biofrontera operating expenses from 2021 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.1B
Amgen (AMGN)	$155.2B
Gilead Sciences (GILD)	$148.2B
Vertex Pharmaceuticals (VRTX)	$94B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$82.7B
GSK (GSK)	$77.1B
Regeneron Pharmaceuticals (REGN)	$59.7B
Alnylam Pharmaceuticals (ALNY)	$57.5B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$26.8B
Insmed (INSM)	$23.2B
Royalty Pharma (RPRX)	$21.1B
Biogen (BIIB)	$19.2B
Incyte (INCY)	$15.3B
Illumina (ILMN)	$14.5B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.7B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Moderna (MRNA)	$10.2B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Exact Sciences (EXAS)	$7.8B
Halozyme Therapeutics (HALO)	$7.8B